Literature DB >> 24302498

Discovery and development of small molecule SHIP phosphatase modulators.

William G Kerr1,2,3, John D Chisholm1, Dennis R Viernes1, Lydia B Choi1.   

Abstract

Inositol phospholipids play an important role in the transfer of signaling information across the cell membrane in eukaryotes. These signals are often governed by the phosphorylation patterns on the inositols, which are mediated by a number of inositol kinases and phosphatases. The src homology 2 (SH2) containing inositol 5-phosphatase (SHIP) plays a central role in these processes, influencing signals delivered through the PI3K/Akt/mTOR pathway. SHIP modulation by small molecules has been implicated as a treatment in a number of human disease states, including cancer, inflammatory diseases, diabetes, atherosclerosis, and Alzheimer's disease. In addition, alteration of SHIP phosphatase activity may provide a means to facilitate bone marrow transplantation and increase blood cell production. This review discusses the cellular signaling pathways and protein-protein interactions that provide the molecular basis for targeting the SHIP enzyme in these disease states. In addition, a comprehensive survey of small molecule modulators of SHIP1 and SHIP2 is provided, with a focus on the structure, potency, selectivity, and solubility properties of these compounds.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  PI3K; SHIP; drug development; enzyme agonist; enzyme inhibition; inositol phosphatase

Mesh:

Substances:

Year:  2013        PMID: 24302498      PMCID: PMC4991215          DOI: 10.1002/med.21305

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  148 in total

Review 1.  SHIPs ahoy.

Authors:  G Krystal; J E Damen; C D Helgason; M Huber; M R Hughes; J Kalesnikoff; V Lam; P Rosten; M D Ware; S Yew; R K Humphries
Journal:  Int J Biochem Cell Biol       Date:  1999-10       Impact factor: 5.085

Review 2.  Phosphoinositide phosphatases: just as important as the kinases.

Authors:  Jennifer M Dyson; Clare G Fedele; Elizabeth M Davies; Jelena Becanovic; Christina A Mitchell
Journal:  Subcell Biochem       Date:  2012

3.  Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell.

Authors:  Joseph A Wahle; Kim H T Paraiso; Robert D Kendig; Harshani R Lawrence; Liwei Chen; Jerry Wu; William G Kerr
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 4.  Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.

Authors:  Luigi Moretti; Eddy S Yang; Kwang W Kim; Bo Lu
Journal:  Drug Resist Updat       Date:  2007-07-12       Impact factor: 18.500

5.  TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1.

Authors:  Qisheng Peng; Shikha Malhotra; James A Torchia; William G Kerr; K Mark Coggeshall; Mary Beth Humphrey
Journal:  Sci Signal       Date:  2010-05-18       Impact factor: 8.192

Review 6.  Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.

Authors:  John G Foster; Matthew D Blunt; Edward Carter; Stephen G Ward
Journal:  Pharmacol Rev       Date:  2012-10       Impact factor: 25.468

7.  Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.

Authors:  Xiao-Jun Qi; Gary M Wildey; Philip H Howe
Journal:  J Biol Chem       Date:  2005-11-10       Impact factor: 5.157

8.  SHIP is required for a functional hematopoietic stem cell niche.

Authors:  Amy L Hazen; Michelle J Smith; Caroline Desponts; Oliver Winter; Katrin Moser; William G Kerr
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

Review 9.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

10.  The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man.

Authors:  Evelyne Marion; Pamela Jane Kaisaki; Valérie Pouillon; Cyril Gueydan; Jonathan C Levy; André Bodson; Georges Krzentowski; Jean-Claude Daubresse; Jean Mockel; Jens Behrends; Geneviève Servais; Claude Szpirer; Véronique Kruys; Dominique Gauguier; Stéphane Schurmans
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

View more
  24 in total

Review 1.  The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease.

Authors:  Ana Raquel Ramos; Somadri Ghosh; Christophe Erneux
Journal:  J Lipid Res       Date:  2018-09-07       Impact factor: 5.922

2.  Friedel-Crafts Alkylation of Indoles with Trichloroacetimidates.

Authors:  Tamie Suzuki; John D Chisholm
Journal:  Tetrahedron Lett       Date:  2019-04-03       Impact factor: 2.415

Review 3.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.

Authors:  William G Kerr; John D Chisholm
Journal:  J Immunol       Date:  2019-01-01       Impact factor: 5.422

4.  Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT.

Authors:  Katarzyna B Leszczynska; Iosifina P Foskolou; Aswin G Abraham; Selvakumar Anbalagan; Céline Tellier; Syed Haider; Paul N Span; Eric E O'Neill; Francesca M Buffa; Ester M Hammond
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

Review 5.  PI3K signaling in Leishmania infections.

Authors:  Peter E Kima
Journal:  Cell Immunol       Date:  2016-09-07       Impact factor: 4.868

6.  The Crohn's disease-associated polymorphism in ATG16L1 (rs2241880) reduces SHIP gene expression and activity in human subjects.

Authors:  E N Ngoh; H K Brugger; M Monajemi; S C Menzies; A F Hirschfeld; K L Del Bel; K Jacobson; P M Lavoie; S E Turvey; L M Sly
Journal:  Genes Immun       Date:  2015-07-30       Impact factor: 2.676

7.  Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).

Authors:  Christopher M Russo; Arijit A Adhikari; Daniel R Wallach; Sandra Fernandes; Amanda N Balch; William G Kerr; John D Chisholm
Journal:  Bioorg Med Chem Lett       Date:  2015-09-15       Impact factor: 2.823

Review 8.  Microglial malfunction: the third rail in the development of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

9.  Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Authors:  Elizabeth A Lemm; Beatriz Valle-Argos; Lindsay D Smith; Johanna Richter; Yohannes Gebreselassie; Matthew J Carter; Jana Karolova; Michael Svaton; Karel Helman; Nicola J Weston-Bell; Laura Karydis; Chris T Williamson; Georg Lenz; Jeremy Pettigrew; Curtis Harwig; Freda K Stevenson; Mark Cragg; Francesco Forconi; Andrew J Steele; Jennifer Cross; Lloyd Mackenzie; Pavel Klener; Graham Packham
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

10.  INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia.

Authors:  Andy P Tsai; Peter Bor-Chian Lin; Chuanpeng Dong; Miguel Moutinho; Brad T Casali; Yunlong Liu; Bruce T Lamb; Gary E Landreth; Adrian L Oblak; Kwangsik Nho
Journal:  Neurobiol Dis       Date:  2021-02-22       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.